Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416310 | 1.00 | MAPT (0.33) | MAPTKMT2AHTTHSD11B1 | |
| SCHEMBL6590839 | 0.88 | CTSL (0.39) | MAPTKMT2AHTT | |
| SCHEMBL7411727 | 0.88 | CTSL (0.39) | MAPTKMT2AHTT | |
| SCHEMBL7413329 | 0.84 | CYP3A4 (0.34) | — | |
| SCHEMBL6590297 | 0.84 | CYP3A4 (0.34) | — | |
| SCHEMBL6588417 | 0.83 | CHRM2 (0.32) | — | |
| SCHEMBL7111617 | 0.83 | CHRM2 (0.32) | — | |
| SCHEMBL6590150 | 0.83 | CCR1 (0.32) | — | |
| SCHEMBL7412446 | 0.82 | NAAA (0.35) | — | |
| SCHEMBL5743591 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1413580-A1 | Furanone derivatives as inhibitors of Cathepsin S | Medivir UK Ltd (GB) | 2004-04-28 | — | — | EP | claimed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | claimed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | claimed |
| EP-1413580-A1 | Furanone derivatives as inhibitors of Cathepsin S | Medivir UK Ltd (GB) | 2004-04-28 | — | — | EP | disclosed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
| EP-1178986-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | Medivir UK Ltd (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000069855-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | MAPT 4747/4885KMT2A 4276/4885HTT 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.